Gentamicin B (GB), a valuable starting material for the preparation of the semisynthetic aminoglycoside antibiotic isepamicin, is produced in trace amounts by the wild-type Micromonospora echinospora. Though the biosynthetic pathway to GB has remained obscure for decades, we have now identified three hidden pathways to GB production via seven hitherto unknown intermediates in M. echinospora. The narrow substrate specificity of a key glycosyltransferase and the C6′-amination enzymes, in combination with the weak and unsynchronized gene expression of the 2′-deamination enzymes, limits GB production in M. echinospora. The crystal structure of the aminotransferase involved in C6′-amination explains its substrate specificity. Some of the new intermediates displayed similar premature termination codon readthrough activity but with reduced toxicity compared to the natural aminoglycoside G418. This work not only led to the discovery of unknown biosynthetic routes to GB, but also demonstrated the potential to mine new aminoglycosides from nature for drug discovery.
A minoglycosides are one of the oldest classes of antibiotics and have been widely used against mycobacteria, staphylococci, and Gram-negative bacteria 1 . However, as with other classes of antibiotics, aminoglycoside resistance among microorganisms has emerged and spread rapidly 2 . To address this challenge, chemically modified aminoglycosides have been developed to overcome deactivation by aminoglycoside-modifying enzymes 3 . For example, dibekacin (1) 4 is the first semisynthetic aminoglycoside derived from kanamycin B (2). Amikacin (3) 5 was developed from kanamycin A (4) in the 1970s, and netilmicin (5) 6 and isepamicin (6) 7 were developed in the 1980s from sisomicin (7) and gentamicin B (GB, 8), respectively. Arbekacin (9) 8 was derived from kanamycin B and marketed in 1990 ( Fig. 1 ). Since then, no new aminoglycoside antibiotics have been approved despite the fact that multidrug resistant (MDR) Gram-negative bacteria are on the rise at an alarming rate 9 . Importantly, the potential for aminoglycosides in the treatment of viral infection 10 and human genetic diseases caused by premature termination codons (PTCs) 11 has been demonstrated, emphasizing the need for the development of more new aminoglycosides.
For generation of new aminoglycoside antibiotics or improvement of the production of valuable natural congeners for use in the synthesis of semisynthetic aminoglycosides, a detailed knowledge of the biosynthetic pathways and the involved enzymes are required 12 . A good example is the recent characterization of the entire kanamycin biosynthetic pathway 13, 14 . Interestingly, manipulation of the kanamycin biosynthetic genes has permitted switching between the major products produced in Streptomyces kanamyceticus 13, 15 . As for gentamicin biosynthesis, gentamicin C congeners are the major products of the wild-type M. echinospora, with virtually no production of GB 16 . Because GB is an important congener used in the preparation of isepamicin, a better understanding of the gentamicin biosynthetic pathways could allow engineering of bacterial strains to produce GB as the major product. Unfortunately, much less is known about the biosynthesis of gentamicins than that of kanamycins, even though both share a biosynthetic route from d-Glc-6-phosphate via 2-deoxystreptamine (DOS, 10) to the common pseudodisaccharide intermediate paromamine (PM, 11) 1 .
Previous studies of gentamicin biosynthesis have shown that the glycosyltransferase GenM1 of M. echinospora catalyzes the transfer of N-acetyl-d-glucosamine (GlcNAc) onto DOS to give 2′-N-acetyl-PM (AcPM, 12), which is converted to PM by the deacetylase GenD 17 . The second glycosyltransferase GenM2 catalyzes glycosylation of PM with xylose to give the pseudotrisaccharide gentamicin A2 (GA2, 13) 17 . Conventionally, the DOS ring is designated as ring II, and the sugar attached at C4 and C6 of DOS are labeled as rings I and III, respectively ( Fig. 1) . Subsequent amination and N-methylation at C3″ of ring III of GA2 are catalyzed by the dehydrogenase GenD2, the aminotransferase GenS2, and the N-methyltransferase GenN in sequence to give gentamicin A (GA, 14). This is followed by C4″-methylation by the C-methyltransferase GenD1 to generate gentamicin X2 (GX2, 15) 18 and C6′-methylation of GX2 by the C-methyltransferase GenK to give G418 (16) 19 ( Supplementary Fig. 1 ). Next, the dehydrogenase GenQ and the aminotransferase GenB1 catalyze the amination at C6′ of GX2 and G418, yielding JI-20A (17) and JI-20Ba (18)/JI-20B (19) , respectively 20, 21 . In addition, the substrate-flexible GenB2 can catalyze the epimerization between both JI-20Ba and JI-20B, and gentamicin C2a (20) and C2 (21) 20, 21 . Recently, GenL has been identified to be responsible for 6′-N-methylation of gentamicin C2 and gentamicin C1a (22) to gentamicin C1 (23) and gentamicin C2b (24) , respectively 22 ( Supplementary Fig. 1 ). Although substantial progress has been made, the biosynthetic pathway to GB remains elusive despite being first discovered in 1972 23 . This is mainly because the general gene knockout approach to identify the biosynthetic genes and to detect the accumulated intermediates cannot be applied in this case because of the low production of GB by the wild-type M. echinospora. Moreover, GB cannot be biotransformed to gentamicin C components by M. echinospora 24 , indicating that GB is not an intermediate in the gentamicin C series pathway but rather a shunt metabolite of gentamicin biosynthesis.
To better understand gentamicin biosynthesis, we have completed, and report herein, the in vitro reconstitution of GB biosynthesis, revealing seven hitherto-unknown gentamicin biosynthetic intermediates and three enigmatic pathways leading to GB. We also identified the limiting factors contributing to the low production yield of GB. Among the new gentamicin intermediates, 2′-deamino-2′-hydroxy-GA2 (2′DGA2, 25), 2′-deamino-2′-hydroxy-GA (2′DGA, 26), and 2′-deamino-2′-hydroxy-GX2 (2′DGX2, 27) exhibited reduced in vitro nephrotoxicity but similar PTC readthrough activity ex vivo compared to G418. Overall, our results uncover both the long-sought hidden biosynthetic pathways to GB and a number of bioactive aminoglycosides that had eluded detection in the past. This study demonstrates that the elucidation of minor biosynthetic pathways can be an alternative strategy to mine for new aminoglycosides that are difficult to access from nature.
results
Discovery of GA2 analogs. We first reasoned that gentamicin biosynthesis may proceed in a fashion analogous to that of kanamycin. In kanamycin biosynthesis, the substrate-flexible glycosyltransferase KanM1 catalyzes the transfer of either UDP-GlcNAc or UDP-Glc onto DOS to generate PM (via AcPM by the deacetylase KanN 1 ) and 2′-deamino-2′-hydroxy-PM (2′DPM, 28), respectively. These two intermediates, PM and 2′DPM, are further 6′-aminated to neamine (6′-amino-6′-deoxy-PM, NM, 29) and 2′-deamino-2′-hydroxy-NM (2′DNM, 30), respectively, by another flexible C6′-dehydrogenaseaminotransferase, KanQ-KanB 13 . Thus, it is conceivable that GB, which is a 2′-deaminated analog of JI-20A, may be generated in a similar manner from 2′DNM through xylosyl transfer by GenM2 (2′DNM → 6′-amino-2′-deamino-6′-deoxy-2′-hydroxy-GA2 (6′A2′DGA2, 31)), C3″-methylamination by GenD2-GenS2-GenN (6′A2′DGA2 → 6′-amino-2′-deamino-6′-deoxy-2′-hydroxy-GA (6′A2′DGA, 32)), and C4″-methylation by GenD1 (6′A2′DGA → GB), assuming that these enzymes possess reasonable substrate promiscuity, typically observed for secondary metabolism enzymes (Figs. 2a and 3a). Therefore, we opted to examine the above hypothesis by in vitro reconstitution of the entire biosynthetic pathway of GB from DOS, whose biosynthesis is well known 1 . Soluble histidinetagged GenM1 and GenM2 were obtained by expression of the corresponding genes in Escherichia coli and Streptomyces venezuelae, respectively ( Supplementary Fig. 2 ). When the purified GenM1 was incubated overnight with DOS in the presence of UDP-GlcNAc or UDP-Glc, the products repectively predicted as AcPM and 2′DPM were separately produced ( Fig. 2a -c). The identities of AcPM and 2′DPM were confirmed by comparing their UPLC-qTOF-HR-MS chromatograms and MS/MS fragmentations with those previously reported for AcPM 13 and those of chemically synthesized authentic 2′DPM, respectively (see Supplementary Note 1 for the chemical synthesis and structural characterization of gentamicin intermediates). Under the same incubation conditions, the corresponding conversion yields of DOS to AcPM and 2′DPM were approximately 54% and 13%, respectively, suggesting that UDP-GlcNAc may be a better glycosyl donor compared to UDP-Glc in the GenM1catalyzed reaction. If correct, this would stand in contrast to results for KanM1 of the kanamycin biosynthetic pathway, in which UDP-Glc appears to be the preferred substrate 13 .
In the kanamycin pathway, the conversion of PM and 2′DPM to NM and 2′DNM is catalyzed by KanQ-KanB. It is thus likely that the KanQ-KanB counterparts in the gentamicin pathway GenQ-GenB1 have similar activities despite GenQ-GenB1 having only been shown to catalyze the C6′-amination of pseudotrisaccharide GX2 in an early experiment 20 . If GenQ-GenB1 are indeed effective for generating NM and 2′DNM from PM and 2′DPM, it would be interesting to know whether these four pseudodisaccharides can all be recognized and processed by the glycosyltransferase GenM2. To probe this possibility, we expressed and purified GenM2 and acquired the four pseudodisaccharides: NM from a commercial source, PM by hydrolysis of paromomycin (33) , and 2′DPM and 2′DNM by chemical synthesis (Supplementary Note 1). Incubation of GenM2 overnight with PM, NM, 2′DNM, and 2′DPM plus UDP-xylose (UDP-Xyl) led to the formation of new UPLC peaks corresponding to their respective 6-O-xylosylated products GA2, 6′-amino-6′-deoxy-GA2 (6′AGA2, 34), 6′A2′DGA2, and 2′DGA2 at conversion yields of approximately 93%, 13%, 8%, and 9%, respectively ( Fig. 2a,d-g ). The structures of GA2, 6′AGA2, 6′A2′DGA2, and 2′DGA2 were identified by UPLC and MS/MS analysis in comparison with the synthesized standards (Supplementary Note 1). These results showed that GenM2 accepts all four pseudodisaccharides as glycosyl acceptors an is apparently most active with PM. It is important to note that of the pseudotrisaccharide products, 6′AGA2, 6′A2′DGA2, and 2′DGA2 have not previously been identified as gentamicin biosynthetic intermediates.
The diverse pathways to analogs of GA and GX2. The C3″methylamination catalyzed by GenD2-GenS2-GenN and the subsequent C4″-methylation catalyzed by GenD1 are required for the biosynthesis of GX2 via GA from GA2 (ref. 18 6′A2′DGA2, and 2′DGA2 to JI-20A, GB, and 2′DGX2, respectively, via the intermediates 6′-amino-6′-deoxy-GA (6′AGA, 35), 6′A2′DGA, and 2′DGA ( Fig. 3a ). To assess this possibility, we expressed the histidine-tagged GenD2, GenS2, GenN, and GenD1 in E. coli ( Supplementary Fig. 2 ). When GenD2, GenS2, and GenN were incubated overnight with GA2 in the presence of NAD + , l-glu-tamine, and S-adenosyl-l-methionine (SAM), the complete conversion of GA2 to a new product was achieved ( Fig. 3b ). This product was consistent with GA based on UPLC retention time as well as HR-MS/MS analysis in comparison with an authentic standard (Supplementary Note 1). Because the product of GenD2-GenS2 (3″-amino-3″-deoxy-GA2) could inhibit the activities of GenD2 
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GenQ-B1 and GenS2 at a very low concentration 18 , these three enzymes need to be assayed together to drive the C3″ modification to complete. As expected, 6′AGA2, 6′A2′DGA2, and 2′DGA2 were respectively converted, in efficiencies equal to the turnover of GA2 to GA, to a series of new gentamicin derivatives, 6′AGA, 6′A2′DGA, and 2′DGA by GenD2-GenS2-GenN ( Fig. 3a ,c-e). These new compounds were isolated from large-scale enzyme reactions, and their structures were confirmed by NMR and UPLC-qTOF-HR-MS spectroscopy (Supplementary Note 1). Upon treatment with GenD1, GA, 6′AGA, 6′A2′DGA, and 2′DGA all underwent C4″methylation, producing new peaks predicted to be GX2, JI-20A, GB, and 2′DGX2, respectively, in nearly quantitative yields ( Fig. 3a ,f-i). The UPLC retention times and MS/MS fragmentation patterns of these new products were identical to those of commercial GX2 and chemically synthesized JI-20A, GB, and 2′DGX2, respectively (Supplementary Note 1). These results demonstrate that GB can be generated by a new biosynthetic pathway via two newly identified intermediates, 6′A2′DGA2 and 6′A2′DGA. Moreover, although 2′DGX2 is a known synthetic product 25 , it has not previously been noted as a gentamicin biosynthetic intermediate.
C6′-amination pathway interconnects the intermediates.
To examine the C6′-amination activity of GenQ-GenB1 toward the two pseudodisaccharides (PM and 2′DPM) and the five pseudotrisaccharides (GA2, GA, 2′DGA2, 2′DGA, and 2′DGX2), we expressed the histidine-tagged GenQ and GenB1 in E. coli and purified ( Supplementary Fig. 2 ). Upon overnight incubation of GenQ-GenB1 with l-glutamine as an amino donor, the natural substrate GX2 was converted into JI-20A in ca. 80% yield. Conversions of GA2, GA, 2′DGA2, 2′DGA, and 2′DGX2 to their C6′-amination products 6′AGA2, 6′AGA, 6′A2′DGA2, 6′A2′DGA, and GB, respectively, by GenQ-GenB1 were also observed ( Fig. 4a-g) . However, the conversion yield for each substrate was low (GA2, 8%; GA, 14%; 2′DGA2, 2%; 2′DGA, 2%; 2′DGX2, 12%). These results suggest that the presence of the 2′-amino and/or the 4″-methyl group in the pseudotrisaccharides seems to be critical for C6′-amination activity of GenQ-GenB1. A similar trend was also observed upon incubation of PM and 2′DPM with GenQ-GenB1. The yields of NM and 2′DNM were 31% and 5%, respectively ( Fig. 4a ,h,i). The greater extent of conversion of PM compared to 2′DPM is similar to that reported for KanQ-KanB in kanamycin biosynthesis 13 . Interestingly, amination of the pseudodisaccharide PM was found to be more extensive compared to both GA2 and GA, which lack the 4″-methyl group. Likewise, 2′DPM was also consumed to a greater degree than 2′DGA2 and 2′DGA. These findings again suggest the importance of the 4′′-methyl group for GenQ-GenB1 activity when the third sugar moiety (ring III) is present. All substrates carrying a 2′-amino group were more completely consumed in the presence of GenQ-GenB1 than their counterparts without a 2′-amino group, implying that the 2′-amino group may also be important for substrate recognition by GenQ-GenB1. Moreover, these results indicate that C6′-amination catalyzed by GenQ-GenB1 can serve to bridge those pathways involving 6′-hydroxylated intermediates with pathways involving 6′-aminated intermediates (Fig. 4a ). A case in point is that GB can be derived from 2′DGX2 by GenQ-GenB1-catalyzed C6′-amination.
The diverse C2′-deamination pathways leading to GB. During the biosynthesis of kanamycin, an α-ketoglutarate-dependent dioxygenase KanJ and a NADPH-dependent reductase KanK act on kanamycin B to produce kanamycin A by C2′-deamination 14 .
Interestingly, heterologous expression of kanJ-kanK in the JI-20Aaccumulating M. echinospora mutant resulted in the production of GB 26 , indicating that GB could also be biosynthesized from JI-20A through C2′-deamination. However, no homologs of the kanJ-kanK genes can be found in the gentamicin gene cluster of M. echinospora. Yet, re-examining the draft genome sequence of M. echinospora led to the identification of two adjacent genes outside of the gentamicin gene cluster that are homologous to kanJ and kanK (55% identity at translated sequence level). They are accordingly designated genJ and genK2, respectively ( Supplementary  Figs 3 and 4 ). Overnight incubation of the histidine-tagged GenJ and GenK2 ( Supplementary Fig. 2 ) with JI-20A, 6′AGA2, and 6′AGA (along with α-ketoglutarate and (NH 4 ) 2 Fe(SO 4 ) 2 ·6H 2 O for GenJ, and NADPH for GenK2) produced GB, 6′A2′DGA2, and 6′A2′DGA, respectively, in nearly quantitative yield (Figs 4a and 5a-c). GenJ-GenK2 also transformed GA2, GA, and GX2 to their C2′-deaminated products 2′DGA2, 2′DGA, and 2′DGX2 in 10%, 67%, and 78% yields, respectively (Figs 4a and 5d-f). In addition, this enzyme pair could also catalyze C2′-deamination of kanamycin B, which bears a 6′-amino group, to kanamycin A as efficiently as JI-20A is converted to GB ( Supplementary Fig. 5 ). Whereas the 6′-amino group in the substrate appears to be important for efficient turnover by the GenJ-GenK2 pair, this does not seem to be the case for ring III, particularly when ring I has a 6′-amino group. These results demonstrated that GB can be biosynthesized via another independent C2′-deamination pathway from JI-20A by the action of the newly identified GenJ-GenK2.
In the above GenJ-GenK2-coupled reactions, 2′-oxo-products generated from the GenJ reaction were detected on the basis of MS/ MS fragmentation patterns ( Supplementary Fig. 6 ). To confirm the identity of these ketone intermediates, we treated the GenJ reaction with JI-20A in the absence of GenK2 with NaBH 4 or NaBD 4 and observed the formation of GB or [2′-2 H]GB (36) ( Supplementary  Fig. 7a,b ). Furthermore, the addition of 10 mM phenylhydrazine after the GenJ reaction led to a phenylhydrazone derivative of 2′-oxo-GB ( Supplementary Fig. 7c ). These results showed that GenJ indeed catalyzes the deamination of JI-20A to form a keto product.
To learn more about the GenJ mechanism, [2′-2 H]JI-20A (37) was chemically prepared (Supplementary Note 1), and upon incubation with GenJ it yielded an unlabeled ketone product, based on ESI-MS analysis ( Supplementary Fig. 8 ). The oxygen dependency of GenJ was also demonstrated by the incorporation of notable amounts of 18 O into JI-20A (32%) under an 18 O-enriched atmosphere (Supplementary Fig. 9 and Supplementary Table 1 ). These findings indicated that GenJ acts as a typical Fe II /α-ketoglutarate-dependent dioxygenase and that the reaction is initiated by the abstraction of a hydrogen atom at C2′ of JI-20A through the reactive [Fe IV = O] species in a mechanism similar to that of KanJ 14 .
To address why the wild-type M. echinospora is a very poor producer of GB despite the high in vitro C2′-deamination activity of GenJ-GenK2 toward JI-20A, we performed transcriptional analysis using semiquantitative RT-PCR. The expression levels of genJ-genK2 and six other gentamicin biosynthetic genes located in different operons in the cluster (genM1, genM2, genP, genK, genE, and genN) were compared in M. echinospora. Transcripts of those genes encoded in the cluster were clearly observed at 60 h, increased up to 72-84 h, and maintained at 96 h. However, transcription of genJ-genK2 was undetectable at 60 h, was slightly detected at 72-84 h, and disappeared at 96 h ( Supplementary Fig. 10 ), indicating that the weak and unsynchronized expression of genJ-genK2 in comparison with other genes in the gentamicin cluster could not support GB biosynthesis in M. echinospora.
Structure of GenB1. A greater substrate specificity for GenM2
and GenQ-GenB1 could explain the limited production of GB in the wild-type M. echinospora strain. As an effort to elucidate the structural basis for C6′-amination efficiency, crystal structures of GenB1 complexed with PLP, PLP/NM, and PLP/JI-20A were solved (Supplementary Table 2 ). GenB1 is a homodimer with monomers consisting of a PLP-binding domain (residues 55-281) and two flanking domains (residues 9-59 and 280-416). The loop (residues 257-262) between α9 and α10 in one monomer forms an edge of the active site in the other monomer ( Fig. 6a ; Supplementary Fig. 11 ). The active site of GenB1 harbors P, R1, R2, and R3 subsites for binding of PLP, ring I, ring II, and ring III of the substrates, respectively (Fig. 6b ).
In the holo-GenB1, PLP is covalently bound to Lys232, and one magnesium ion in the R1 subsite occupies a negatively charged hole formed by Asp345, Asp395, and the C-terminal end of α11 ( Supplementary Fig. 12 ). Upon binding of NM, an external aldimine formed between PLP and ring I of NM ( Fig. 6c ; Supplementary  Fig. 13 ). Interestingly, the 2′-amino group of ring I in NM replaces the magnesium ion to form polar interactions with Asp345, Asp395, and the backbone oxygen of Ala393. Given that GenB1 prefers substrates carrying a 2′-amino group to those with a 2′-hydroxyl group (Fig. 4) , the anchoring of the 2′-amino group to the negatively charged hole explains this bias. Tyr132 in the R2 subsite forms C-H/π stacking interactions with the DOS moiety (ring II) in NM (Fig. 6d ).
The binding modes of PLP and ring I of JI-20A in the GenB1-PLP-JI-20A complex are virtually identical to those in the GenB1-PLP-NM complex. However, the GenB1-JI-20A complex structure revealed a semi-sphere-like R3 subsite that accommodates ring III of JI-20A ( Fig. 6e ; Supplementary Fig. 14) . The methyl groups at C3″ and C4″ of ring III face the methyl pocket of the R3 subsite lined by Leu156, Trp391, Trp415, and the C-terminal region (Fig. 6e) . The R3 methyl pocket may form favorable contacts with hydrophobic groups and is probably responsible for the enhanced amination efficiency of GenB1 toward substrates with methyl substituents including GX2 and 2′DGX2 over GA2 and 2′DGA2 (Fig. 4) . To study the importance of the R1 negatively charged hole and the R3 methyl pocket, we replaced Asp345 and Asp395 with leucine and mutated Trp391 and Trp415 to alanine. Indeed, an approximately 50% decrease in the C6′-amination activity toward GX2 was observed with the four mutant proteins ( Supplementary Fig. 15 ).
Ring II in both JI-20A and NM is packed against Tyr132. The 3-amino group of NM forms an ion pair with Asp395, whereas ring II in JI-20A is flipped ~180°, losing the favorable interaction ( Supplementary Fig. 16 ). If ring II of JI-20A holds the same conformation as that of NM, steric clash would occur between ring III of JI-20A and the active site. Hence, the presence of ring III in JI-20A affects the binding mode of ring II ( Supplementary Fig. 16 ).
The roughly 2-4-fold greater consumption of PM and 2′DPM compared to both GA2/GA and 2′DGA2/2′DGA (Fig. 4) is consistent with the hypothesis that ring II of PM and 2′DPM binds to the R2 subsite in the favorable binding mode, whereas ring II of GA2/GA and 2′DGA2/2′DGA is in the less favorable binding mode due to the presence of ring III. Binding between GenB1 and GA2/ GA or 2′DGA2/2′DGA may be further weakened by the absence of methyl groups on ring III, preventing favorable occupancy of the R3 methyl pocket. Together, the R1 negatively charged hole, the R3 methyl pocket, and the two distinct binding modes of ring II in the R2 subsite are all expected to be important for substrate recognition by GenB1.
In vitro toxicity and bioactivity of new intermediates. Because the major therapeutic disadvantages of aminoglycosides are their high nephrotoxicity and ototoxicity 27 , to assess the therapeutic potential of the newly identified GB derivatives we analyzed their toxicities using three mammalian kidney cell lines HEK-293, LCC-PK1, and COS-7. G418, which is one of the strongest readthrough inducers among natural aminoglycosides 28 , was used as a control. The half-maximal lethal concentration (LC 50 ) values for 2′DGA2, 2′DGA, and 2′DGX2 were approximately 1.2-1.3fold higher than that of G418 in the three cell lines tested. 6′AGA2, 6′AGA, and JI-20A displayed approximately 1.2-fold lower LC 50 compared to G418 in human HEK-293 cells ( Supplementary  Fig. 17) . These results display a correlation of reduced toxicity to fewer amino groups, and are consistent with the structure-toxicity relationships observed previously for aminoglycosides 29 . It was also noted that only the number and not the position of the free amino groups in ring I is the key determinant for cell toxicity. The structure of ring III does not appear to substantially contribute to cell toxicity. The antibiotic activities of the gentamicin biosynthetic intermediates were tested against four gentamicin-susceptible and -resistant bacteria (Enterococcus fecalis, Pseudomonas aeruginosa, Staphylococcus aureus, and E. coli; Supplementary Table 3) . All compounds tested (compounds 8, 13-15, 17, 25-27, 31, 32, 34, and 35 ) were inactive against the tested strains except that GB, GX2, JI-20A, 6′A2′DGA, and 6′AGA exhibited weak activity against gentamicin-susceptible S. aureus and E. coli. The level of antibiotic activity follows the order JI-20A > GB > 6′AGA > 6′A2′DGA > GX2, indicating the importance of the 2′-amino, 6′-amino, 3″-methylamino, and 4″-methyl groups for antibacterial activity. Next, we examined whether these new intermediates could induce PTC readthrough in human cells. Primary human cystic fibrosis bronchial epithelial cells (cystic fibrosis transmembrane conductance regulator (CFTR); ∆F508/W1282X) were exposed to 25 μM of compounds 8, 13-17, 25-27, 31, 32, 34, and 35 for up to 2 d, and the comparative ratio of full-length to truncated CFTR was quantitatively measured using HPLC-ESI-MS. All compounds induced similar levels of PTC readthrough compared to G418 except for JI-20A and GB, which exhibited relatively weak readthrough activity ( Supplementary Fig. 18 ). These results showed that 2′DGA2, 2′DGA, and 2′DGX2 can induce substantial levels of readthrough but with evidently reduced toxicity compared to G418.
Discussion
Our in vitro results now establish that GB can be assembled via three independent biosynthetic routes involving seven newly identified intermediates: 25-27, 31, 32, 34, and 35 (Fig. 4a ). The minor biosynthetic intermediates 2′DGA2, 6′A2′DGA2, and 6′AGA2 are generated through xylosylation of the pseudodisaccharides 2′DPM, 2′DNM, and NM, respectively, by the not-so-promiscuous GenM2. These compounds can then be converted to their corresponding new GA analogs, 2′DGA, 6′A2′DGA, and 6′AGA, by the substrateflexible GenD2-GenS2-GenN system. Subsequent reaction with the GenQ-GenB1 pair can produce small amounts of 6′A2′DGA2, 6′A2′DGA, 6′AGA2, and 6′AGA from 2′DGA2, 2′DGA, GA2, and GA, and the known product JI-20A from GX2 (ref. 20 ). From this point forward, three pathways can lead to GB production: C4″methylation of 6′A2′DGA by the C-methyltransferase GenD1, C6′-amination by GenQ-GenB1 of 2′DGX2, which is derived from 2′DGA by GenD1, and C2′-deamination of JI-20A catalyzed by GenJ-GenK2. In addition, GenJ-GenK2 could also deaminate GA2, GA, GX2, 6′AGA2, and 6′AGA to their 2′-deaminated products. These results uncovered an interwoven GB biosynthetic network showing that all 12 pseudotrisaccharide intermediates are interconnected by GenQ-GenB1, GenD2-GenS2, GenN, GenD1, and GenJ-GenK2 (Fig. 4a) .
The present studies also suggest that the limited in vivo production of GB in the wild-type M. echinospora is due to the high substrate specificity with respect to both the GenQ-GenB1 pair involved in C6′-amination and the glycosyltransferase GenM2 involved in the attachment of xylose to the pseudodisaccharide acceptor. GenM2 exhibits an increased catalytic preference for PM compared to 2′DPM, NM, and 2′DNM, resulting in decreased biosynthesis of the minor pseudotrisaccharides 2′DGA2, 6′AGA2, and 6′A2′DGA2. Furthermore, the C2′-amino and C4″-methyl groups are likely to be important for substrate recognition and subsequent C6′-amination by GenQ-GenB1. This makes GX2 the most abundant and the only productive biosynthetic intermediate for GB (Fig. 4a) . The weak and unsynchronized expression of genJ-genK2 located outside the gentamicin cluster also restricts in vivo production of GB, although their translated products show sufficient in vitro 2′-deamination activity toward JI-20A and the other 6′-aminated pseudotrisaccharides, 6′AGA2 and 6′AGA.
The C6′-amination step is catalyzed by GenQ-GenB1. Although we could not determine the structure of GenQ and did not investigate whether the key determinant of substrate specificity is GenB1, GenQ, or both during C6′-amination, the structures of GenB1 provided important insights into the substrate preference of this aminotransferase. BtrR 30 from Bacillus circulans and RbmB 31 from Streptomyces ribosidificus involved in DOS biosynthesis are PLP-dependent sugar aminotransferases functionally relevant to GenB1. The structure of GenB1 is superimposed onto those of RbmB and BtrR with r.m.s. deviations of 3.6 and 3.5 Å, respectively ( Supplementary Fig. 19 ). The large r.m.s. deviation values reflect the low sequence identities (~12%) between GenB1 and RbmB/ BtrR ( Supplementary Fig. 20) . The active sites of RbmB and BtrR have space only for a single sugar ring (ring II) covalently attached to PLP ( Supplementary Fig. 21 ), which is in contrast to the three subsites in GenB1 (Fig. 6 ). This disparity is related to the fact that the C-terminal extension of RbmB and BtrR covers the region corresponding to the R1 and R3 subsites of GenB1 ( Supplementary  Fig. 21 ). Accordingly, the unique subsite organization in the large active site of GenB1 is specifically tailored for its substrate promiscuity and preference. Although we did not perform a mechanistic study of GenB1, structural observations indicate that GenB1 shares a reaction mechanism with other PLP-dependent transaminases ( Supplementary Fig. 22 ). Another structure of GenB1 was also reported independently during the revision of this article 32 .
Compared to G418, the new gentamicin analogs 2′DGA2, 2′DGA, and 2′DGX2 have a reduced toxicity profile while maintaining a similar PTC readthrough activity. It has been shown that installing the (S)-4-amino-2-hydroxybutyric acid (AHBA) moiety at the 1-N position 33 and a methyl group at C6′ (refs. 33, 34 ) are effective for improving the termination suppression activity and reducing the toxicity of aminoglycosides. In particular, it was recently reported that the minor component gentamicin B1 (6′-methyl-GB, 38) possesses greater PTC readthrough activity than the gentamicin C series 35 . Therefore, it is highly likely that these new analogs, such as 2′DGA2, 2′DGA, and 2′DGX2, could be candidates for future development of aminoglycosides with improved readthrough activity and reduced toxicity through the installation of a 1-N-AHBA moiety using the enzymes responsible for its construction in the butirosin biosynthetic pathway 13, [36] [37] [38] and a 6′-methyl group catalyzed by GenK 19 .
Taken together, results reported herein are important, as they provide detailed genetic and molecular insights into enhancing the production of GB. Possible in vivo strategies to increase the biosynthesis of GB include protein engineering of GenB1 (or GenQ) and GenM2 to broaden their substrate specificities, as well as construction of a genK-genP deletion mutant to accumulate the precursor JI-20A and overexpression of genJ-genK2 to increase 2′-deamination activity. In an early report, application of the latter strategy led to the substantially enhanced production of GB in the engineered M. echinospora strain 26 . Thus far, only 150 aminoglycosides, including structurally similar congeners 3,39 , have been identified since the discovery of the first aminoglycoside in 1943 (ref. 40 ). The scarcity of this class of compounds is partly due to the fact that aminoglycoside biosynthetic gene clusters are not commonly found in the genome of actinomycetes 41 , and their isolation is particularly challenging compared to many other types of natural products. Our successful efforts at mining the minor biosynthetic intermediates of GB demonstrate the usefulness of this method to discover new aminoglycosides. This alternate approach may be further exploited to expand the diversity of this important class of antibiotics.
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Methods
Materials, bacterial strains, and culture conditions. DOS, UDP-GlcNAc, and NM were purchased from GeneChem Inc. (Daejeon, Republic of Korea All other chemicals were of the highest purity available. Bacterial strains and plasmids used in this study are listed in Supplementary  Table 4 . The gentamicin-producing M. echinospora ATCC 15835 (ref. 42 ) was obtained from the American Type Culture Collection (Manassas, VA, USA). For genomic DNA isolation and cultivation, M. echinospora was grown for 5 d at 28 °C in ATCC 172 medium (1% glucose, 0.5% yeast extract, 2% soluble starch, 0.5% N-Z amine, and 0.2% CaCO 3 ).
E. coli DH5α 43 and plasmid pGEM-T Easy Vector (Promega, Madison, WI, USA) were used for routine subcloning. The pET expression vectors, such as pET15b and pET28a, were purchased from Novagen (Madison, WI, USA). For expression of the recombinant proteins (GenM1, GenD2, GenS2, GenN, GenD1, GenQ, GenB1, GenJ, and GenK2), the E. coli BL21(DE3) (Novagen), E. coli BL21(DE3)pLysS (Novagen), E. coli Rosetta gami TM2 (DE3) (Novagen) and E. coli ArcticExpress(DE3) (Agilent technologies, Santa Clara, CA, USA) were used as heterologous hosts. The E. coli strains were grown in LB liquid medium. Ampicillin (50 μg/ml), chloramphenicol (25 μg/ml), gentamicin (20 μg/ml), and kanamycin (50 μg/ml) were selectively added to the growth media as required. For the recombinant GenM2, the high-copy-number E. coli-Streptomyces shuttle vector pSE34 containing the constitutive ermE* promoter plus a thiostrepton resistance marker was used for expression 44 . S. venezuelae ATCC 15439 (ref. 45 ), which was used as a heterologous host for preparing recombinant GenM2, was grown in liquid R2YE 46 .
Chemical synthesis. The chemical synthesis and structures of GB, GA2, JI-20A, 2′DGA2, 2′DGX2, 2′DPM, 2′DNM, 6′A2′DGA2, 6′AGA2, and [2′-2 H]-JI-20A are described in the Supplementary Note 1.
UPLC-qTOF-HR-MS analysis and structural identification of gentamicin biosynthetic intermediates.
UPLC-qTOF-HR-MS analysis of the gentamicin biosynthetic intermediates generated by chemical and enzymatic synthesis was performed on a Waters XEVO G2S Q-TOF mass spectrometer coupled with a Waters Acquity UPLC system equipped with an Xselect CSH column XP (2.1 × 100 mm, 2.5 μm) consisting of an Acquity I-Class system. A gradient elution using solvent A (50 mM ammonium-TFA, pH 2.0) and solvent B (50% aq. acetonitrile with 50 mM ammonium-TFA, pH 2.0) as the mobile phase at a flow rate of 0.2 ml/min at 40 °C was applied. The MS system was operated in ESI with a positive ionization mode. The typical operating parameters were as follows: analyzer, resolution mode; capillary voltage (volt.), 3.0 kV; sampling cone volt., 30 V; source temperature (temp.), 120 °C, source offset temp., 80 °C; desolvation temp., 300 °C; cone gas flow, 10 L/h; desolvation gas flow, 600 L/h: helium collision gas. The analyzer was operated with an extended dynamic range at 60,000 resolution (FWHM at m/z 556) with an acquisition time of 0.1 s. Leucine enkephalin (400 pg/μl, 50% aq. acetonitrile with 0.1% formic acid) as a lockspray was infused at a rate of 5 μl/min for mass correction. Mass spectra were acquired with a scan range of 50-600 amu with scan time of 0.1 s.
NMR spectra of GB, PM, GA2, GA, GX2, JI-20A, 2′DGA2, 2′DGA, 2′DGX2, 2′DPM, 2′DNM, 6′A2′DGA2, 6′A2′DGA, 6′AGA2, and 6′AGA were acquired using a Bruker Ascend 800 MHz spectrometer or a Varian INOVA 500 MHz spectrometer. Details regarding the characterization of gentamicin biosynthetic intermediates are described in Supplementary Note 1. The retention behaviors of compounds 8, 11-15, 17, 25-28, 30-32, 34, and 35 on UPLC-qTOF-HR-MS and data including MS/MS and NMR spectra are described in Supplementary Note 1.
Genome sequencing of M. echinospora ATCC 15835. To determine the genome sequence of strain ATCC 15835, sequencing was performed using the Ion Torrent PGM sequencer by GenoTech Corporation (Daejeon, Republic of Korea). The genomic libraries (~200 bp) were constructed by Ion Xpress Plus Fragment Library Kit, and nucleotide sequences with 115-fold coverage of the ATCC 15835 genome were generated. A genome assembly was accomplished by the CLC Genomics Workbench (CLC bio, Inc.). Genome annotation was performed using NewGAS (New Genome Annotation Systems), which is a bioinformatic analysis and database program consisting of automatic genome prediction, annotation pipeline, and NewGAS browser. RNAmmer and tRNAscan-s.e.m. were respectively used to detect rRNA and tRNA genes. Protein-coding genes were predicted by Glimmer 3.0. AutoFACT was used for automatic functional assignment of the coding sequences with the public databases, GenBank, COG, UniRef90, and KEGG. , the genD2, genS2, genN, genD1, and genB1 genes were codonoptimized for expression in E. coli and synthesized from DNA 2.0 (Menlo Park, CA, USA). Meanwhile, the four genes encoding GenM1, GenQ, GenJ, and GenK2 were obtained by PCR amplification using the genomic DNA of M. echinospora ATCC 15385 as a template. Each primer sequence contained a restriction site to facilitate cloning of the resulting DNA fragment (see Supplementary Table 5 for oligonucleotide primers). All DNA fragments were cloned into pJExpress404, pET15b, or pET28a to encode a histidine-tagged construct (see Supplementary  Table 4 ).
Construction of protein expression plasmids. For recombinant protein expression
To obtain the recombinant GenM2, a PCR-amplified DNA fragment (see Supplementary Table 5 for oligonucleotide primers) was cloned into pET28a to generate a histidine-tagged construct, and the digested genM2 fragment was ligated into the complementary sites of pSE34 (ref. 44 ; see Supplementary Table 4 ).
Overexpression of recombinant proteins. For the expression of GenM1, the expression plasmid pGENM1 was introduced into E. coli ArcticExpress(DE3), and the ArcticExpress(DE3)/pGENM1 strain (see Supplementary Table 4 ) was grown in LB medium supplemented with 50 μg/ml kanamycin and 20 μg/ml gentamicin. Each liter of culture was inoculated with 10 ml of overnight starter culture. The culture was grown at 37 °C to an optical density at 600 nm (OD 600 ) of 0.6, and then expression was induced with 1 mM IPTG. At the same time, the incubation temperature was shifted from 37 to 13 °C, and the culture was grown for another 24 h. Recombinant GenM1 was purified as described below. Typically, approximately 0.2 mg of GenM1 was obtained from 1 L of culture (see Supplementary Fig. 2) .
For the expression and purification of GenM2, the expression plasmid pGENM2 was transformed into S. venezuelae, yielding the corresponding recombinant strain, S. venezuelae/pGENM2 (see Supplementary Table 4 ). S. venezuelae protoplast formation and transformation procedures were performed as previously described 46 . The recombinant strain of S. venezuelae harboring pGENM2 was grown in R2YE medium at 30 °C for 5 d. Recombinant GenM2 was purified as described below. Typically, approximately 0.5 mg of GenM2 was obtained from 1 L of culture (see Supplementary Fig. 2) .
For the expression and purification of GenD2, GenS2, and GenN, the synthesized expression plasmids pGEND2 and pGENN were individually introduced into E. coli BL21(DE3), whereas the pGENS2 was introduced into E. coli BL21(DE3)pLysS. The recombinant BL21(DE3)/pGEND2 and BL21(DE3)/ pGENN strains (see Supplementary Table 4 ) were grown in LB medium supplemented with 50 μg/ml kanamycin. The BL21(DE3)pLysS/pGENS2 strain (see Supplementary Table 4 ) was grown in the same medium in the presence of 50 μg/ ml ampicillin and 25 μg/ml chloramphenicol. Each liter of culture was inoculated with 10 ml of overnight starter culture, and the resulting mixture was grown at 37 °C to an OD 600 of 0.6. Overexpression of the desired proteins was induced by 0.5 mM IPTG at 18 °C for another 12 h. Recombinant GenD2, GenS2, and GenN were purified as described below. Typically, approximately 3 mg, 2.5 mg, and 3 mg of purified GenD2, GenS2, and GenN were obtained, respectively, from 1 L of culture (see Supplementary Fig. 2) .
For the expression and purification of GenD1, the expression plasmid pGEND1 was introduced into E. coli BL21(DE3)pLysS, and the BL21(DE3) pLysS/pGEND1 strain (see Supplementary Table 4 ) was grown in LB medium supplemented with 50 μg/ml ampicillin and 25 μg/ml chloramphenicol. Each liter of culture was inoculated with 10 ml of overnight starter culture. The culture was grown at 37 °C to an OD 600 of 0.6, then expression was induced with 1 mM IPTG and 2 mM Fe(II)SO 4 . The culture was grown for another 3 h. Recombinant GenD1 was purified and then reconstituted with iron and sulfide in an anaerobic glovebox according to an established procedure 18 . Typically, approximately 18 mg of GenD1 was obtained from 1 L of culture (see Supplementary Fig. 2) .
For the expression and purification of GenQ and GenB1, the expression plasmids pGENQ and pGENB1 were introduced into E. coli Rosetta gami TM2 (DE3) and E. coli BL21(DE3)pLysS, respectively. Each liter of culture was inoculated with 10 ml of overnight starter culture. The Rosetta gami TM2 (DE3)/pGENQ strain (see Supplementary Table 4 ) was grown in LB medium containing 50 μg/ml kanamycin at 37 °C to an OD 600 of 0.6, and then expression was induced with 0.5 mM IPTG at 18 °C for another 12 h. Meanwhile, the BL21(DE3)pLysS/pGENB1 strain (see Supplementary Table 4 ) was cultured in LB medium supplemented with 50 μg/ml ampicillin and 25 μg/ml chloramphenicol until an OD 600 of 0.6 was reached. IPTG was then added to the culture to a final concentration of 0.5 mM, and the culture continued to grow at 18 °C for another 16 h. Recombinant GenQ and GenB1 were also purified as described below. Typically, approximately 1.5 mg and 2 mg of purified GenQ and GenB1, respectively, were obtained from 1 L of culture (see Supplementary Fig. 2) .
For the expression and purification of GenJ and GenK2, the expression plasmids pGENJ and pGENK2 were separately introduced into E. coli BL21(DE3). The recombinant BL21(DE3)/pGENJ and BL21(DE3)/pGENK2 strains (see Supplementary Table 4 ) were grown in LB medium supplemented with 50 μg/ml kanamycin. Each liter of culture was inoculated with 10 ml of overnight starter culture, and the culture was grown at 37 °C to an OD 600 of 0.6. Overexpression of the proteins was induced by 1 mM IPTG at 16 °C for another 20 h. Recombinant GenJ and GenK2 were purified as described below. Typically, approximately 7 mg and 4 mg of purified GenJ and GenK2 were obtained, respectively, from 1 L of culture (see Supplementary Fig. 2) .
Protein purification. Cells were harvested by centrifugation (2 min at 20,000 r.p.m.), resuspended in lysis buffer (300 mM NaCl, 10 mM imidazole, 50 mM sodium phosphate, pH 8.0), and then lysed by sonication for 5 min using a 2 s on/2 s off cycle. The lysate was clarified by centrifugation (30 min at 20,000 r.p.m.), and the clarified cell lysate was passed through a column of Ni-nitrilotriacetic acid (NTA) agarose (Qiagen, Valencia, California, USA). After washing the column with washing buffer (300 mM NaCl, 40 mM imidazole, 50 mM sodium phosphate, pH 8.0), histidine-tagged recombinant proteins were eluted with elution buffer (300 mM NaCl, 500 mM imidazole, 50 mM sodium phosphate, pH 8.0). Imidazole was removed from the purified recombinant protein solution using a PD10 column (GE Healthcare, Piscataway, NJ, USA) with Tris buffer (20 mM Tris-HCl, 250 mM NaCl, 10% glycerol, pH 7.9). The purified proteins were concentrated using an Amicon Ultracel 10 K molecular weight cut-off spin filter (Millipore, Bedford, MA, USA), and then stored at −80 °C. Sodium dodecyl sulfate-PAGE (SDS-PAGE) analysis was employed to ascertain the purity of protein. Protein concentration was determined by the Bradford protein assay using bovine serum albumin as a standard.
Enzyme assays. First glycosylation by GenM1 was performed in 50 mM sodium phosphate buffer (pH 8.0) containing 0.5 mM DOS, 20 mM glycosyl donor (UDP-Glc or UDP-GlcNAc), 50 μM purified GenM1, and 5 mM MgCl 2 at 30 °C for 12 h.
Second glycosylation by GenM2 was performed in 100 mM potassium phosphate buffer (pH 8.0) containing 5 mM glycosyl acceptor (PM, 2′DPM, NM, or 2′DNM), 1.8 mM UDP-Xyl, 0.2 mM purified GenM2, and 10 mM MgCl 2 at 37 °C for 12 h.
C3″-methylamination by GenD2-GenS2-GenN was performed in 50 mM Tris-HCl (pH 7.5) containing 0.1 mM substrate (GA2, 2′DGA2, 6′A2′DGA2, or 6′AGA2), 20 μM each enzyme, 2 mM NAD + , 2 mM l-glutamine, and 2 mM SAM at 30 °C for 12 h. C4″-methylation by GenD1 was performed in 50 mM Tris-HCl (pH 8.0) containing 0.1 mM substrate (GA, 2′DGA, 6′A2′DGA, or 6′AGA), 15 μM purified reconstituted GenD1 (according to an established procedure 19 ), 1 mM methylcobalamin, 1 mM benzyl viologen, 10 mM DTT, 4 mM NADPH, and 4 mM SAM. Assay was carried out in an anaerobic chamber (25 °C) for 12 h.
GenQ-GenB1-mediated C6′-amination was performed in 50 mM Tris-HCl (pH 8.0) containing 0.1 mM GX2, 10 μM each enzyme, and 2 mM l-glutamine at 30 °C for 12 h. For the seven substrates showing the weak GenQ-GenB1-mediated C6′-amination activity (PM, GA2, GA, 2′DGA2, 2′DGA, 2′DGX2, or 2′DPM), reactions were carried out by supplementing 0.1 mM of each enzyme.
GenJ-GenK2-mediated C2′-deamination was performed in reaction buffer (40 mM Tris-HCl, 200 mM KCl, 10% glycerol, pH 7.5) containing 0.1 mM substrate (GA2, GA, GX2, JI-20A, 6′AGA2, or 6′AGA), 1.5 μM each enzyme, 1 mM α-ketoglutarate, 1 mM NADPH, and 1 mM (NH 4 ) 2 Fe(SO 4 ) 2 ·6H 2 O at 28 °C for 12 h.
The reaction was quenched with chloroform and centrifuged at 13,000 r.p.m. for 10 min. The supernatant containing the product of interest was extracted using OASIS MCX SPE cleanup 16 , reconstituted with water, and then analyzed by UPLC-qTOF-HR-MS as described above. Independent experiments were performed five or more times. The conversion yield was calculated by dividing the molar equivalent of a product formed by the molar equivalent of the consumption of its reactant. The integrated area under curve (AUC) from the UPLC-qTOF-HR-MS chromatogram was calculated. Calibration curves of each gentamicin intermediate were generated using chemically synthesized, commercially available, or enzymatically synthesized compounds, and were used to convert AUC into the amount of each compound.
Production of 2′DGA, 6′A2′DGA, and 6′AGA by large scale enzyme reactions.
A series of new gentamicin biosynthetic intermediates, 2′DGA, 6′A2′DGA, and 6′AGA were formed from the respective 2′DGA2, 6′A2′DGA2, and 6′AGA2 by one-pot enzymatic reaction. Purified GenD2-GenS2-GenN (40 μM) was incubated with 11 mM substrate (2′DGA2, 6′A2′DGA2, or 6′AGA2), 2 mM NAD + , 2 mM l-glutamine, and 2 mM SAM in 50 mM Tris-HCl (pH 7.5) at 30 °C for 12 h. The reaction was quenched with chloroform and centrifuged at 13,000 r.p.m. for 10 min. The resulting supernatant containing the product of interest was extracted using OASIS MCX SPE cleanup 16 and then subjected to UPLC-qTOF-HR-MS analysis. Further reaction was performed until substrate was converted completely.
To obtain these new intermediates (2′DGA, 6′A2′DGA, and 6′AGA), HPLC purification was done using an analytical Kromasil 1005C18 column (4.6 × 250 mm, 5 μm) on an YL9100 HPLC system (YL Instrument Co. Ltd., Republic of Korea) consisting of a YL9110 gradient pump coupled with a YL9160 photo diode array detector with 1024 channels and a YL9181 ELSD detector. The fraction containing 2′DGA (3.3 mg), 6′A2′DGA (1.8 mg), and 6′AGA (2.4 mg) was purified by analytical HPLC employing 2% aq. MeCN with 0.05% TFA or 10% aq. MeCN with 10 mM HFBA as the mobile phase with a flow rate of 0.7 ml/min to yield the pure compounds.
GenJ-catalyzed deamination reaction for mechanistic study. Reactions to determine the activity of GenJ in the deamination of JI-20A to form a keto intermediate were performed by reduction of the product with NaBH 4 or NaBD 4 for 2 h before analysis, or by derivatization of the product with phenylhydrazine. Specifically, 40 μM GenJ was incubated with 1 mM JI-20A, 1 mM α-ketoglutarate, and 1 mM (NH 4 ) 2 Fe(SO 4 ) 2 •6H 2 O in the presence of 200 mM KCl, 10% glycerol, and 40 mM Tris-HCl buffer (pH 7.5) at room temperature for 20 h. Excess NaBD 4 or NaBH 4 was added into the enzyme assay solution and reacted on ice for 45 min. The reaction was quenched by passage through a YM-10 Microcon centrifugal filter and then subjected to ESI-MS analysis. In a separate experiment, the GenJ reaction was treated with 10 mM phenylhydrazine for 2 h. After dinitrophenyl (DNP) derivatization 14 , the MS measurement was carried out by direct injection into an Agilent 6530 Accurate Mass QTOF-MS at 0.15 ml/min. The results are illustrated in Supplementary Fig. 7 .
To determine the mechanism of GenJ-catalyzed deamination and establish the site of the reaction of JI-20A, reactions were carried out with 1 mM [2′-2 H]-JI-20A using the same conditions described above (see Supplementary Fig. 8 ).
The GenJ assays were also conducted under 18 O-enriched atmospheres to confirm the oxygen-dependency of GenJ catalysis. Reactions were performed by supplementing 16 O 2 /H 2
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